Navigation Links
New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes
Date:11/21/2008

New data presented at the 61st Annual Scientific Meeting of the Gerontological Society of America showed JANUVIA™ (sitagliptin), a diabetes medicine from Merck & Co., Inc., significantly reduced blood sugar levels in elderly patients with type 2 diabetes and was not associated with hypoglycemia (low blood sugar). In this study of 206 patients aged 65 to 96 years, there were no reports of hypoglycemia in either the JANUVIA or the placebo groups. Advanced age contributes to the risk of hypoglycemia.

NATIONAL HARBOR, Md. (Business Wire EON) November 21, 2008 -- JANUVIA is indicated, as an adjunct to diet and exercise, to improve glycemic control in adult patients with type 2 diabetes. JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. JANUVIA has not been studied in combination with insulin. JANUVIA is contraindicated in patients with a history of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis and angioedema. As is typical with other anti-hyperglycemic agents used in combination with a sulfonylurea, when JANUVIA is used in combination with a sulfonylurea, a class of medications known to cause hypoglycemia, the incidence of hypoglycemia was increased over that of placebo. Therefore, a lower dose of sulfonylurea may be required to reduce the risk of hypoglycemia.

"The elderly population presents challenges for the treatment of type 2 diabetes, as various factors can affect the ability to lower these patients' blood sugar to target levels," said lead study investigator Nir Barzilai, M.D., director of the Institute for Aging Research and Animal Physiology Core, Diabetes Research Training Center at the Albert Einstein College of Medicine. "In this study, JANUVIA effectively helped lower blood glucose levels and was not associated with hypoglycemia."

JANUVIA significa
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine news :

1. STAAR Surgical Forms Team of Leading Ophthalmic Surgeons to Study the Use of Collamer(R) Material for Accommodating Intraocular Lenses
2. Landmark study defines benefits of early HIV testing and treatment for infected infants
3. Study identifies causes of bone loss in breast cancer survivors
4. New Study by BioTrends Highlights Practice Management Shifts Among Canadian Nephrologists
5. Study Suggests Need for More Aggressive Outpatient Monitoring of Patients Hearts When Cause of Stroke is Unclear
6. Rutgers researchers study cites media violence as critical risk factor for aggression
7. Brigham and Womens Researchers Partner with Vocantas to use CallAssure in Clinical Research Study
8. Analyst Available to Comment on New JUPITER Study That Shows AstraZenecas Crestor Significantly Reduces CV Risk
9. New Study Finds CO2 Ablative Fractional Resurfacing Safe And Effective For Deep Acne Scarring
10. Study investigates Gore-tex-type device to stop strokes and mini-strokes
11. The smart way to study

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 
New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes
(Date:11/8/2009)...her Costs and Crushing Taxes Nail Nation,s Job Cre...ire/ -- In response to U.S. House passage of the h...Entrepreneurship Council (SBE Council) president &...ment: ,, "Make no mistake, those voting for H....with higher costs and crushing taxes and penalties...
(Date:11/8/2009)... Freeze-drying of biopharmaceutica...uga, Ontario facility. , ...llner, President and CEO of Therapure Biopharma In...very of a commercial scale pharmaceutical grade fr...eeze drying (lyophilization) available for contrac...
(Date:11/8/2009)...tion,s largest network of Hispanic health advocate...form in 2009 ,, WASHINGTON, Nov. 7 /PRNewswire...ntatives showed they have heard the voice of Ameri...e for America Act. Now the Senate must deliver, wi...are reform," said Dr. Jane L. Delgado, President a...
(Date:11/8/2009)...RP Praises House Passage of Health Care Reform Bil...dicare, improve coverage for all Americans ,, ...the United States House of Representatives passed ...legislation that would strengthen Medicare for sen... that prices millions of Americans out of affordab...
(Date:11/7/2009)...HINGTON , Nov. 7 Spe...n support of H.R. 3962, the Affordable Health Care...slation later tonight. Below are the Speaker,s re...w, is an historic moment for our nation and for Am... every party and political philosophy -- as far ba...
Breaking Medicine News(10 mins):Health News:Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer 2Health News:National Alliance for Hispanic Health President and CEO Applauds House Action, Calls on Senate to Pass Health Reform in 2009 2Health News:AARP Illinois Key Vote News Alert 2Health News:AARP Illinois Key Vote News Alert 3Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 2Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 3Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 4
...on of leading European breast cancer organizations... of scientific conference, which aims to ensure br...e from cutting-edge research. , At the first IMPA...plement their results will discuss how to bring em...
...Industry Veteran Will Focus on Broader Product Dis...SAN FRANCISCO, March 31 DecisionView, Inc., the l... for the Life Sciences industry, today announced t...ently, he held the role of Chairman for DecisionVi...
...CAN HAVE COMPLETE CONFIDENCE IN THE SAFETY AND SEC...RDS , , LOS ANGELES, March 31 MMR Information Sy...ugh its wholly-owned operating subsidiary, MyMedic... deposit box storage solutions ( www.myesafedepos...
... Marketing Technology Solutions (MTS... the company,s new Chief Executive Officer. MTS i...eting and specializes in connecting engaged health...s strong financial performance to date. , ...
...oftware helps small corporations keep compliant wi...Iccomplish, Inc announces the availability of "Qui...the tediousness out of corporate record-keeping an...n of the cost of hiring a corporate attorney. , ...
...rch Releases Study showing state of the senior hea...esearch recently released the 2009 Senior Market ...pping behavior in the senior health insurance mark...rance. The study found that at a $5 dollar premium...
Other Medicine News:Health News:IMPAKT Breast Cancer Conference 2Health News:DecisionView Board of Directors Appoints James P. Scullion as CEO and President 2Health News:MyMedicalRecords Offers Privacy Insurance on Personal Health Record and Virtual EsafeDepositBox Products 2Health News:MyMedicalRecords Offers Privacy Insurance on Personal Health Record and Virtual EsafeDepositBox Products 3Health News:MyMedicalRecords Offers Privacy Insurance on Personal Health Record and Virtual EsafeDepositBox Products 4Health News:Marketing Technology Solutions Primed for Future Growth with Appointment of Rob Rebak as New CEO 2Health News:Marketing Technology Solutions Primed for Future Growth with Appointment of Rob Rebak as New CEO 3Health News:Automate Corporate Minutes and Resolutions; Stop IRS Woes Before They Happen 2Health News:Changes in Medicare Advantage Reimbursement May Prompt Members to Shop for New Plans 2
(Date:11/6/2009).../ -- California American Water has designated the ...in" week for its San Diego County service area as ...d private agencies alike toward the common mission...e water supplies. ,, California American Water,...p off expired or unwanted pharmaceuticals free of ...
(Date:11/5/2009)...e/ -- Althea Technologies, Inc., a leading provide...opharmaceutical products announced the addition of...,s platform of services, which will be overseen by...of Formulation Development. This investment in an ...entists, along with new laboratory facilities and ...
(Date:11/5/2009)...ire/ -- ARKRAY, Inc., the world,s 5th largest manu...y announced that it has received 510(k) clearance ...ew GLUCOCARD Vital blood glucose monitoring system...KRAY will make available for distribution in early...ent to the existing GLUCOCARD line of products, an...
Breaking Medicine Technology:California American Water Celebrates 'No Drugs Down the Drain' Week in San Diego 2Althea Technologies Adds Formulation Development to Its Integrated Offering of Contract Services 2ARKRAY, Inc. Receives FDA Clearance for New GLUCOCARD(R) Vital(TM) Blood Glucose Monitoring System 2Pelosi Remarks at Press Conference on Health Care Reform for the Middle Class 51551 1Pelosi Remarks at Press Conference on Health Care Reform for the Middle Class 51551 2Pelosi Remarks at Press Conference on Health Care Reform for the Middle Class 51551 3Pelosi Remarks at Press Conference on Health Care Reform for the Middle Class 51551 4Why African Americans are at greater risk of hypertension and kidney disease 51546 1Why African Americans are at greater risk of hypertension and kidney disease 51546 2American Red Cross President to Address National Press Club Luncheon 51542 1American Red Cross President to Address National Press Club Luncheon 51542 2
...al Results Disclosed, SAN DIEGO, Oct. 20 Trius T...eloping "Best-in-Class" drugs for the,treatment of...t the results,of multiple studies on its lead prog...be presented in eighteen presentations at the upco...l Agents and Chemotherapy (ICAAC),and Infectious D...
...., Oct. 17 CeNeRx BioPharma,Inc., a clinical stag...e,treatments for diseases of the central nervous s...se II clinical trial for its lead product candidat... disorder (MDD). Tyrima is,a selective and reversi...s,or reversible inhibitors of monoamine oxidase A ...
Other Medicine Technology:Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA 2Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA 3CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM) 2CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM) 3
ACULAR® 5 mL
cardiofax GEM Basic-level interpretive resting ECG
cardiofax Q Mid-level interpretive resting ECG
Cruise Control
Medicine Products: